In accordance with this, Duffy et al. [107] conducted a study and demonstrated the activation of the immune system following the introduction of checkpoint inhibitors and the accumulation of intra-tumoral CD8+ T-cells following RF ablation; they thereby presented the first clinical evidence of synergism of the checkpoint inhibitor tremelimumab and RF-ablation in the management of advanced hepatocellular carcinomas. This evidence concerns the gene CD8A and hepatocellular carcinoma.